Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)

Revenue by Product

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Cancer Immunotherapy Drugs	1.90B	Log In
Cancer Immunotherapy Drugs Growth	13737.27%	Log In

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
South Korea	1.90B	Log In
South Korea Growth	13737.27%	Log In